Printer Friendly

CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B

 PROVIDENCE, R.I., Feb. 10 /PRNewswire/ -- CytoTherapeutics, Inc. (NASDAQ: CTII) and Genetic Therapy, Inc. (NASDAQ: GTII) announced today that they have entered into a collaborative research agreement to investigate the encapsulation of Genetic Therapy's gene-altered cells for the production of Factor IX to treat hemophilia B.
 CytoTherapeutics will encapsulate Genetic Therapy's gene-altered cells within its proprietary semi-permeable polymer membranes. The purpose of this first phase will be to establish Factor IX production in the encapsulated system, as well as cell growth characteristics.
 According to Seth Rudnick, M.D., Chief Executive Officer of CytoTherapeutics, "This collaboration is an opportunity to combine two broad-based technologies: CytoTherapeutics' ability to encapsulate living cells for implantation in the body, and Genetic Therapy's technology for altering the genetic composition of cells to produce therapeutic benefit.
 "This is also an opportunity to demonstrate the range of potential applications for our encapsulation technology," he added.
 Hemophilia B is an inherited blood disorder characterized by the body's inability to produce a key protein, Factor IX, necessary for coagulation. Hemophilia B, a rare form, is one of a family of genetic blood diseases which are estimated to affect 20,000 people in the U.S. alone.
 Genetic Therapy, Inc. based in Gaithersburg, MD, is a leader in the development of human gene therapy products for genetic and acquired diseases. Founded in 1986, GTI and its collaborators represent one of the largest groups of scientists dedicated to research and development in this field. The Company's shares have been publicly traded since July, 1991.
 CytoTherapeutics is a leader in the research and development of a novel approach to cell therapy for the treatment of severe, chronic diseases. The Company is developing a new class of therapeutic products based on its core technology of membrane-encapsulated living cells, which can be implanted into patients to supply critical biomolecules. CytoTherapeutics' CNS (Central Nervous System) products in development include CereCRIB(tm), for the treatment of severe, chronic pain, and NeuroCRIB(tm), for the treatment of Parkinson's disease, in addition to its Type I diabetes product in development, EndoCRIB(tm).
 -0- 2/10/93
 /CONTACT: Thomas G. Wiggans, 401-272-3310 ext. 2152 or Elizabeth Razee, 401-272-3310 ext. 2132 of CytoTherapeutics, Inc./
 (CTII GTII)


CO: Cytotherapeutics; Gene Therapy Inc. ST: Rhode Island, Maryland IN: MTC SU:

TM -- NE011 -- 5276 02/10/93 15:11 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1993
Words:386
Previous Article:10,000 JETS FOR FREEDOM
Next Article:FIDELITY MANAGEMENT AND RESEARCH COMPANY PURCHASES AGNICO-EAGLE MINES COMMON STOCK
Topics:


Related Articles
CYTOTHERAPEUTICS AND DRS. WEISS AND REYNOLDS TO INVESTIGATE USES OF NEURAL STEM CELLS TO TREAT NEURODEGENERATIVE DISORDERS
TRANSKARYOTIC THERAPIES AND GENETICS INSTITUTE COLLABORATE ON COMMERCIALIZATION OF GENE THERAPY PRODUCT FOR HEMOPHILIA A
GENETICS INSTITUTE'S rhFACTOR IX ADVANCES TO GLOBAL PHASE 3 CLINICAL TRIALS
Genentech and Baxter Collaborate to Develop Hemophilia Gene Therapy
Cell Genesys Issued Broad Patent for Adeno-Associated Viral Vector Technology
Avigen further expands its extensive adeno-associated viral patent portfolio.
Cell Genesys issued patent for adeno-associated viral gene therapy.
Avigen licenses adeno-associated virus vector technology to Stratagene.
Cell Genesys exclusively licenses technology for liver-directed Aav gene therapy from University of Washington.
American Home and Targeted Genetics establish partnership for B-domain deleted factor VIII hemophilia gene Therapy.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters